376 related articles for article (PubMed ID: 22900989)
21. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Zhao SP; Yu BL; Peng DQ; Huo Y
Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
[TBL] [Abstract][Full Text] [Related]
22. [Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):553-8. PubMed ID: 24078569
[TBL] [Abstract][Full Text] [Related]
23. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
24. Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
Gu GL; Xu XL; Yang QY; Zeng RL
Med Sci Monit; 2014 Dec; 20():2824-9. PubMed ID: 25547030
[TBL] [Abstract][Full Text] [Related]
25. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
26. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
30. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
31. Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.
Shimada A; Kimura H; Oida K; Kanehara H; Bando Y; Sakamoto S; Wakasugi T; Saga T; Ito Y; Kamiyama K; Mikami D; Iwano M; Hirano T; Yoshida H
Lipids Health Dis; 2016 Mar; 15():57. PubMed ID: 26984517
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM
Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
34. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
35. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
36. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
van Venrooij FV; Stolk RP; Banga JD; Sijmonsma TP; van Tol A; Erkelens DW; Dallinga-Thie GM;
Diabetes Care; 2003 Apr; 26(4):1216-23. PubMed ID: 12663600
[TBL] [Abstract][Full Text] [Related]
37. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
[TBL] [Abstract][Full Text] [Related]
38. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
39. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
40. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]